Subtopic Deep Dive
TRK Fusion Sarcomas
Research Guide
What is TRK Fusion Sarcomas?
TRK Fusion Sarcomas are soft tissue sarcomas characterized by NTRK gene fusions driving oncogenesis, treatable with TRK inhibitors like larotrectinib.
NTRK fusions occur in rare sarcomas, enabling targeted therapy with larotrectinib showing durable responses across tumor types (Drilon et al., 2018, 2596 citations). Detection relies on genomic profiling and WHO classification updates (Sbaraglia et al., 2020, 925 citations; von Mehren et al., 2022, 1099 citations). Over 10 key papers document fusion prevalence and inhibitor efficacy in pediatric and adult cases.
Why It Matters
Larotrectinib achieves 75% objective response rates in TRK fusion-positive sarcomas, offering options for patients without standard therapies (Drilon et al., 2018). Neoadjuvant use enables tumor downsizing for resection in locally advanced cases (DuBois et al., 2018). NCCN guidelines integrate TRK testing into sarcoma management, improving outcomes in rare subtypes (von Mehren et al., 2022). Expert consensus from World Sarcoma Network standardizes diagnosis and treatment (Demetri et al., 2020). Genomic profiling identifies actionable fusions in 1-2% of sarcomas (Gounder et al., 2022).
Key Research Challenges
Fusion Detection Sensitivity
Low prevalence requires sensitive methods like NGS or FISH for NTRK fusions in heterogeneous sarcomas (Gounder et al., 2022). False negatives occur in small biopsies, complicating diagnosis (Demetri et al., 2020). Standardized panels improve yield but face tissue limitations (Sbaraglia et al., 2020).
Acquired Resistance Mechanisms
Secondary mutations in TRK kinases emerge post-larotrectinib, reducing efficacy (Drilon et al., 2018). Combination strategies lack prospective data in sarcomas (von Mehren et al., 2022). Monitoring needs serial biopsies or liquid biopsies (Demetri et al., 2020).
Pediatric Trial Generalization
Phase 1/2 data show high responses in children, but adult sarcoma extrapolation is limited (Laetsch et al., 2018). Congenital cases like mesoblastic nephroma highlight early fusions (Rubin et al., 1998). Long-term safety data remain immature (DuBois et al., 2018).
Essential Papers
Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children
Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar et al. · 2018 · New England Journal of Medicine · 2.6K citations
Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo Oncology and others; ...
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, John M. Kane, Mark Agulnik et al. · 2022 · Journal of the National Comprehensive Cancer Network · 1.1K citations
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blo...
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
Marta Sbaraglia, Elena Bellan, Angelo Paolo Dei Tos · 2020 · Pathologica · 925 citations
Mesenchymal tumours represent one of the most challenging field of diagnostic pathology and refinement of classification schemes plays a key role in improving the quality of pathologic diagnosis an...
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Theodore W. Laetsch, Steven G. DuBois, Leo Mascarenhas et al. · 2018 · The Lancet Oncology · 534 citations
Congenital Mesoblastic Nephroma t(12;15) Is Associated withETV6-NTRK3 Gene Fusion
Brian P. Rubin, Changjie Chen, Thomas W. Morgan et al. · 1998 · American Journal Of Pathology · 440 citations
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
Mrinal M. Gounder, Narasimhan P. Agaram, Sally E. Trabucco et al. · 2022 · Nature Communications · 165 citations
A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma
Richard D Riley, Susan A. Burchill, Keith R. Abrams et al. · 2003 · Health Technology Assessment · 161 citations
T he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies i...
Reading Guide
Foundational Papers
Start with Rubin et al. (1998, 440 citations) for ETV6-NTRK3 discovery in mesoblastic nephroma; Riggi et al. (2007) for sarcoma genetics context.
Recent Advances
Drilon et al. (2018, 2596 citations) for larotrectinib efficacy; von Mehren et al. (2022, NCCN) for guidelines; Demetri et al. (2020) for expert recommendations.
Core Methods
NGS genomic profiling (Gounder et al., 2022); TRK inhibitor therapy (larotrectinib dosing from Drilon et al., 2018); WHO classification of fusions (Sbaraglia et al., 2020).
How PapersFlow Helps You Research TRK Fusion Sarcomas
Discover & Search
Research Agent uses searchPapers('TRK fusion sarcoma larotrectinib') to retrieve Drilon et al. (2018) with 2596 citations, then citationGraph to map 500+ citing works and findSimilarPapers for neoadjuvant cases like DuBois et al. (2018). exaSearch uncovers unpublished trial data linked to NCT02122913.
Analyze & Verify
Analysis Agent applies readPaperContent on Drilon et al. (2018) to extract response rates, verifyResponse with CoVe against von Mehren et al. (2022) NCCN guidelines, and runPythonAnalysis to plot survival curves from Kaplan-Meier data using pandas/matplotlib. GRADE grading scores larotrectinib evidence as high-quality from phase 2 trials.
Synthesize & Write
Synthesis Agent detects gaps in resistance data across Drilon et al. (2018) and Demetri et al. (2020), flags contradictions in fusion prevalence. Writing Agent uses latexEditText for manuscript sections, latexSyncCitations to integrate 20 sarcoma papers, latexCompile for PDF, and exportMermaid for TRK signaling pathway diagrams.
Use Cases
"Extract and plot response rates from larotrectinib trials in TRK sarcomas"
Research Agent → searchPapers → Analysis Agent → readPaperContent(Drilon 2018) → runPythonAnalysis(pandas parse tables, matplotlib barplot of ORR by sarcoma subtype) → researcher gets CSV of rates and publication-ready figure.
"Write LaTeX review section on TRK inhibitors in sarcoma guidelines"
Synthesis Agent → gap detection → Writing Agent → latexEditText(draft text) → latexSyncCitations(Drilon 2018, von Mehren 2022) → latexCompile → researcher gets compiled PDF with synced references and figure captions.
"Find open-source NGS pipelines for NTRK fusion detection from sarcoma papers"
Research Agent → searchPapers('NTRK fusion NGS sarcoma') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets curated list of 5 validated pipelines with README summaries and adaptation scripts.
Automated Workflows
Deep Research workflow runs systematic review: searchPapers(50+ TRK sarcoma papers) → citationGraph → GRADE all → structured report with evidence tables. DeepScan applies 7-step analysis to Drilon et al. (2018): readPaperContent → verifyResponse(CoVe) → runPythonAnalysis(survival stats) → synthesis. Theorizer generates hypotheses on next-gen TRK inhibitors from resistance patterns in Demetri et al. (2020).
Frequently Asked Questions
What defines TRK Fusion Sarcomas?
Sarcomas with NTRK1/2/3 fusions like ETV6-NTRK3, identified via NGS or FISH, responsive to larotrectinib (Demetri et al., 2020).
What methods detect NTRK fusions?
Genomic profiling with NGS panels, IHC screening, or FISH; NCCN recommends in advanced sarcomas (von Mehren et al., 2022; Gounder et al., 2022).
What are key papers?
Drilon et al. (2018, 2596 citations) shows larotrectinib efficacy; Laetsch et al. (2018) pediatric results; Rubin et al. (1998) foundational ETV6-NTRK3 fusion.
What open problems exist?
Overcoming acquired resistance via kinase mutations; optimizing neoadjuvant timing; expanding to adults from pediatric data (DuBois et al., 2018; Demetri et al., 2020).
Research Sarcoma Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching TRK Fusion Sarcomas with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Sarcoma Diagnosis and Treatment Research Guide